| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Consolidated net loss and comprehensive loss | -6,344 | -9,784 | -15,778 | -34,045 |
| Depreciation and amortization | 120 | 19 | 56 | 298 |
| Loss on disposal of property and equipment | NaN | -185 | NaN | NaN |
| Change in fair value of warrant liability | -2,674 | -831 | 2,119 | -1,583 |
| Change in fair value of ppas | -273 | 406 | NaN | NaN |
| Commitment fee under sepa | NaN | 282 | NaN | NaN |
| Financing costs related to ppas | NaN | 742 | NaN | NaN |
| Stock-based compensation | 956 | 1,120 | 1,292 | 3,022 |
| Prepaid expenses and other assets | 237 | -455 | -1,056 | 383 |
| Accounts payable and accrued expenses | 3,069 | -747 | 1,016 | 2,535 |
| Accounts payable and accrued expenses - related parties | NaN | NaN | 0 | NaN |
| Right-of-use assets and lease liabilities, net | 116 | 238 | 358 | -252 |
| Net cash used in operating activities | -5,267 | -7,915 | -9,881 | -30,408 |
| Proceeds from issuance of common stock and warrants, net of issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock under employee stock purchase plan | NaN | 53 | 0 | 47 |
| Proceeds from ppas | NaN | 7,125 | NaN | NaN |
| Proceeds from issuance of common stock under sepa | 413 | NaN | NaN | NaN |
| Payment of financing costs related to issuance of common stock, ppas and sepa | 289 | 453 | 0 | 444 |
| Payments for taxes related to net settlement of equity awards | 14 | 12 | 6 | 34 |
| Net cash provided by (used in) financing activities | 110 | 6,713 | -6 | -431 |
| Net decrease in cash and cash equivalents | -5,157 | -1,202 | -9,887 | -30,839 |
| Cash and cash equivalents, beginning of period | 7,118 | 8,320 | 49,046 | NaN |
| Cash and cash equivalents, end of period | 1,961 | 7,118 | 8,320 | NaN |
BioAtla, Inc. (BCAB)
BioAtla, Inc. (BCAB)